title: [Olanzapine in manic/mixed patients with or without substance abuse].
abstract: OBJECTIVE
  To evaluate the efficacy of olanzapine in patients in their manic/mixed phase with or without comorbidity with substance abuse/dependence disorder.
  
  
  METHODS
  In this observational, controlled, prospective study, 60 patients with a DSM-IV-TR diagnosis of bipolar disorder, manic/mixed episode (30 patients with and 30 patient without comorbidity with a substance abuse/dependence disorder) were treated with olanzapine, evaluated at discharge, and followed-up for 8 weeks. Efficacy of olanzapine was assessed by comparing the proportion of responders (an at least 50% drop in Young Mania Rating Scale [YMRS] score from baseline) and remitters (YMRS ≤ 12 and Hamilton Depression Rating Scale [HAM-D] ≤ 8) in both groups. Craving and days of abuse/use were assessed with Visual Analogue Scale (VAS) and Time-line Follow-Back (TLFB), respectively.
  
  
  RESULTS
  Differences in response and remission percentages were statistically not significant at discharge and during follow-up. A reduction of days of abuse has been observed in the drug-abuse group, while craving was only slightly decreased.
  
  
  CONCLUSIONS
  These results suggest that olanzapine is effective in both groups and its efficacy in reducing the days of abuse appears to be independent from its action on craving.
authors.affiliation: Dipartimento NESMOS, II Facolà di Medicina e Chirurgia, Ospedale Sant Andrea, Sapienza Università di Roma. gabriele.sani@justmail.it
authors.forename: Gabriele
authors.initials: G
authors.lastname: Sani
authors.forename: Alessio
authors.initials: A
authors.lastname: Simonetti
authors.forename: Giulia
authors.initials: G
authors.lastname: Serra
authors.forename: Andrea
authors.initials: A
authors.lastname: Solfanelli
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Girardi
authors.forename: Delfina
authors.initials: D
authors.lastname: Janiri
authors.forename: Emanuela
authors.initials: E
authors.lastname: Danese
authors.forename: Chiara
authors.initials: C
authors.lastname: Rapinesi
authors.forename: Roberto
authors.initials: R
authors.lastname: Tatarelli
authors.forename: Paolo
authors.initials: P
authors.lastname: Girardi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000150:complications* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D011446:Prospective Studies; D019966:Substance-Related Disorders / Q000150:complications*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine